organization

JANSSEN PHARMACEUTICA NV

102 projects, page 1 of 21
  • project . 2019 - 2023
    Funder: EC Project Code: 861278
    Overall Budget: 1,292,900 EURFunder Contribution: 1,292,900 EUR
    Open Access mandate for Publications
    Partners: TU Dortmund University, JANSSEN PHARMACEUTICA NV, UL

    LongActNow will design a novel platform technology for the development of long acting (LA) suspensions of complex active pharmaceutical ingredients (API), involving innovative manipulation of API crystal formation and growth and solvent removal. LA formulations have bec...

  • project . 2017 - 2021
    Funder: EC Project Code: 683144
    Overall Budget: 1,997,920 EURFunder Contribution: 1,997,920 EUR
    Open Access mandate for Publications
    Partners: Ghent University, VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY, JANSSEN PHARMACEUTICA NV

    Programmed cell death is essential for homeostasis, and its deregulation contributes to human disease. Inflammasome-induced pyroptosis of infected macrophages contributes to host defense against infections, but the concomitant release of inflammatory danger signals and ...

  • project . 2018 - 2020
    Funder: EC Project Code: 820588
    Overall Budget: 2,935,000 EURFunder Contribution: 2,054,500 EUR
    Open Access mandate for Publications
    Partners: JANSSEN PHARMACEUTICA NV, PDS PATHOLOGY DATA SYSTEMS AG, DECIPHEX LIMITED

    Drug discovery is a time consuming, expensive and risky process. Each drug to market must undergo safety/ toxicity testing in animals which yields thousands of tissue sections that currently must be assessed manually by a trained veterinary pathology. However, there is ...

  • project . 2014 - 2020
    Funder: EC Project Code: 115847
    Overall Budget: 20,402,800 EURFunder Contribution: 20,328,900 EUR
    Open Access mandate for Publications
    Partners: WORLD VISION OF IRELAND, LSHTM, Grameen Foundation, JANSSEN PHARMACEUTICA NV

    Communication strategy and tools for optimizing the impact of Ebola vaccination deployment. The EBODAC consortium consists of 4 partners: Janssen (EFPIA), London School of Hygiene and Tropical Medicine (LSHTM), World Vision of Ireland and Grameen Foundation . These part...

  • project . 2015 - 2019
    Funder: EC Project Code: 676144
    Overall Budget: 3,846,740 EURFunder Contribution: 3,846,740 EUR
    Open Access mandate for Publications
    Partners: UMIL, UNIVERSITE DE BORDEAUX, AXON NEUROSCIENCE SE, DZNE, JANSSEN PHARMACEUTICA NV, Karolinska Institutet Innovations (Sweden)

    Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programm...

102 projects, page 1 of 21
Any information missing or wrong?Report an Issue